(ii) Although ELISA validation analysis was performed, further in-depth validation is required in larger and more diverse HD cohorts and in other NDs to determine the specificity and sensitivity of CAP1 and CAPZB as potential HD biomarkers. Here, CAP1 is linked to Huntington disease.